Clinical Trials
20 trialsNCT06119581 2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06494241 2026-06-02
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
AstraZeneca
Active not recruiting
NCT07279935 2026-06-01
REVIVE
AstraZeneca
Phase 4 Recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06376084 2026-05-19
FOREFRONT
AstraZeneca
Active not recruiting
NCT05379985 2026-05-15
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT05462717 2026-05-15
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Active not recruiting
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT06004440 2026-04-24
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
Active not recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT07407933 2026-04-09
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06841874 2025-12-24
Tale EAP
Nuvation Bio Inc.
No longer available
NCT06145750 2025-11-24
FIRSTLUNG
Delfi Diagnostics Inc.
Phase NA Completed
NCT07162883 2025-09-09
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05890872 2025-08-20
AFFINITY
Galvanize Therapeutics, Inc.
Phase NA Completed